RxDoctor Payments Data

Ashan Manohar, MD

Gastroenterology · Onancock, VANPI 1295725836

Payments from drug & device makers

$2,690in general payments, 2019–2025

Across 111 payments — averaging $24.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$807
  • Gilead$265
  • Janssen Scientific Affairs, LLC$250
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$212
  • Pfizer$199
  • Conmed Corporation$173
  • plus $785 from 13 others

What the payments were for

  • Food & beverage$2,690100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,690 in reported general payments places this provider in the 40th percentile of 473 gastroenterology providers in Virginia.

See all gastroenterology providers in Virginia

Medicare billing

Part B allowed, 2024
$90,323
Medicare patients
414
Services billed
740

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab11$286,733
EntyvioVedolizumab13$114,623
XifaxanRifaximin11$35,261
ViberziEluxadoline15$21,628
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates56$3,561
Omeprazole190$2,254
Budesonide DrBudesonide11$1,985
Mesalamine13$1,831
Lansoprazole20$1,633
Famotidine60$785
Pantoprazole Sodium88$675
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl38$576
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl30$493
Clarithromycin12$443
Amoxicillin12$70

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$138$286,73311 claims
Takeda Pharmaceuticals U.S.A., Inc.Entyvio$130$114,62313 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$212$35,26111 claims
AbbVieViberzi$807$21,62815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 473 gastroenterology providers in Virginia.

Other gastroenterology in Onancock

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →